Page 26 - Helicobacter pylori and Gastric Cancer: From Tumor microenvironment to Immunotherapy

Chapter 1
General introduction
24
19
true concerning immune checkpoints inhibitors in Gastric cancer. Thus I study the use of anti-PD-1, anti-PD-L1, and anti-CTLA- 4 monoclonal antibodies in gastric cancer. In addition, I aim to link the genetic makeup of H. pylori infection to disease progression. Finally and speculatively I also aim to investigate the potential usefulness of unconventional model systems for a better understanding of the mechanisms potentially constraining immune activity, which may further boost effectivity of such immunocheckpoint-targeting drugs. The results of these efforts will be integrated into a final discussion as well. In conjunction I hope this thesis will foster new thinking on the management of gastric cancer.
References
1. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86.
2. Siegel, R., et al., Cancer statistics, 2014. CA Cancer J Clin, 2014. 64(1): p. 9-29.
3. Hanahan, D. and Robert A. Weinberg, Hallmarks of Cancer: The Next Generation. Cell. 144(5): p. 646-674.
4. Hanahan, D. and R.A. Weinberg, The Hallmarks of Cancer. Cell, 2000. 100(1): p. 57-70.
5. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108.
6. Ajani, J.A., et al., Gastric adenocarcinoma. Nat Rev Dis Primers, 2017. 3: p. 17036.
7. Jemal, A., et al., Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 2010. 19(8): p. 1893-907.
8. Majidi, A., et al., Cancer research priorities and gaps in Iran: the influence of cancer burden on cancer research outputs between 1997 and 2014. Public Health, 2017. 144: p. 42-47.
9. Woods, L.M., et al., Evidence against the proposition that “UK cancer survival statistics are misleading”: simulation study with National Cancer Registry data. Bmj, 2011. 342.
10. Parkin, D.M., et al., Global cancer statistics, 2002. CA Cancer J Clin, 2005. 55(2): p. 74-108.